# Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

> **NCT07375563** · PHASE3 · RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 5 (estimated)

## Conditions studied

- Neuroblastoma (NB)
- Ganglioneuroblastoma

## Interventions

- **COMBINATION_PRODUCT:** Dinutuximab beta, temozolomide, irinotecan, autologous NK cell
- **COMBINATION_PRODUCT:** irinotecan, temozolomide, dinutuximab beta, NK-cell product

## Key facts

- **NCT ID:** NCT07375563
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2026-12-15
- **Final completion:** 2028-11-19
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07375563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07375563, "Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07375563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*